Company Focus
LabCorp
Latest LabCorp News
Pharmaceutical
The US Federal Trade Commission has withdraw its appeal Laboratory Corporation of America's (NYSE: LH) 2010 $57.5 million acquisition of Westcliff Medical Laboratories (The Pharma Letter December 3, 2010). Although LabCorp consummated the acquisition in June 2010, the FTC was seeking the federal court injunction to prevent LabCorp from integrating the companies pending the outcome of administrative litigation. The FTC also has withdrawn the matter from administrative adjudication - a step that stops the trial proceedings, but does not conclude the case. 28 March 2011
Related News
Insights
Company Spotlight
A clinical-stage biotech company advancing next generation, potentially curative cell therapies for cancer patients.
Latest News & Features of interest to LabCorp
Pharmaceutical
Robert F.Kennedy Jr. has been confirmed as the new secretary of the Department of Health and Human Services (HHS) after a closely contested vote in the US Senate. 14 February 2025
Pharmaceutical
French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine it Is developing that will results in a significant impairment charge. 13 February 2025
Biotechnology
In its annual results statement, Galapagos chief financial officer Thad Huston said the firm is moving ahead with a planned split into two publicly-traded companies. 13 February 2025
Biotechnology
US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 12 February 2025
Biotechnology
US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary endpoint in the marginal zone lymphoma (MZL) cohort. 11 February 2025
Pharmaceutical
News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical company focused on immune-mediated diseases. Last week also saw the release of fourth-quarter and full-year 2024 financial results by many pharma companies, including the US giants Merck & Co and Pfizer, as well as the two biggest players in the fast-growing weight management sector, Novo Nordisk and Eli Lilly. 9 February 2025
Biotechnology
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International Region at Gilead and Kite Oncology. Mr Santoro outlines the company’s efforts to expand access to innovative CAR T-cell therapies in the Middle East. 8 February 2025
Biotechnology
Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec) for adults living with hemophilia B. 7 February 2025
Pharmaceutical
Netherlands-based Bilthoven Biologicals, the Dutch subsidiary of the Serum Institute of India and a leading end-to-end manufacturer of viral and bacterial vaccines, has officially inaugurated its pandemic preparedness vaccine facilities. 7 February 2025
Biotechnology
California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant improvement in the Bayley-III raw scores for the subdomains of cognition, receptive communication and expressive communication in patients with Sanfilippo syndrome type A (MPS IIIA) compared to natural history data from untreated patients. 6 February 2025
Latest In Brief for LabCorp
Biotechnology
US health officials are reportedly reexamining a $590 million agreement awarded to Moderna for the development of its bird flu vaccine, according to sources cited by Bloomberg. The review is part of a broader government effort to scrutinize spending on mRNA-based vaccines, the technology behind Moderna’s COVID-19 shot. 28 February 2025
Latest Relevant Ones To Watch News
Shares of US biotech 2seventy Bio skyrocketed almost 76% to $4.92 today, as it agreed to a takeover bid from US pharma major Bristol Myers Squibb, which is looking to enhance its CAR T-cell therapy business. 11 March 2025
21 February 2025
8 January 2025
26 November 2024
19 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze